Juli 2022: Laut der neuesten Studie von Emergen Research erreichte der globale Markt für CAR-T-Zelltherapie im Jahr 1.29 eine Größe von 2021 Milliarden US-Dollar und wird im Prognosezeitraum voraussichtlich eine Umsatzwachstumsrate von 24.9 Prozent verzeichnen. Es wird erwartet, dass die weltweit steigende Krebsinzidenz sowie die steigende krebsbedingte Sterblichkeit im Prognosezeitraum die Haupttreiber des Umsatzwachstums im globalen CAR-T-Zelltherapiemarkt sein werden. Die rasante Ausweitung der klinischen Studienaktivitäten, die Zunahme von Fusionen und Übernahmen sowie der Reiz von Börsengängen sind alles Faktoren, die zum Umsatzwachstum auf dem globalen Markt für CAR-T-Zelltherapie beitragen.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global CAR-T-Zell-Therapie market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the CAR-T-Zell-Therapie market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Weitere wichtige Erkenntnisse aus dem Bericht deuten darauf hin
In 2021, the segment of diffuse large B-cell Lymphom was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with chimäre Antigenrezeptor-T-Zelltherapie, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell Non-Hodgkin-Lymphome who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Die wichtigsten Unternehmen, die derzeit auf dem Markt tätig sind, werden in diesem Bericht weiter untersucht, ebenso wie ihre Unternehmensprofile, Produktportfolios, Expansionsstrategien und strategischen Allianzen. Einige Beispiele für diese Art von Allianzen sind Fusionen und Übernahmen, Kooperationen und Joint Ventures. Darüber hinaus bietet es Highlights zu den Erfolgen und der Finanzlage des Unternehmens sowie Einblicke in die Marktreichweite und die globale Position des Unternehmens.
Auf dem globalen Markt für CAR-T-Zelltherapie profilierte Unternehmen:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
Lesen Sie mehr über den globalen Marktbericht für CAR-T-Zelltherapie unter: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
